Eli Lilly Statistics
Total Valuation
Eli Lilly has a market cap or net worth of $943.99 billion. The enterprise value is $976.34 billion.
| Market Cap | 943.99B |
| Enterprise Value | 976.34B |
Important Dates
The next estimated earnings date is Thursday, February 5, 2026, before market open.
| Earnings Date | Feb 5, 2026 |
| Ex-Dividend Date | Feb 13, 2026 |
Share Statistics
Eli Lilly has 895.38 million shares outstanding. The number of shares has decreased by -0.41% in one year.
| Current Share Class | 895.38M |
| Shares Outstanding | 895.38M |
| Shares Change (YoY) | -0.41% |
| Shares Change (QoQ) | -0.11% |
| Owned by Insiders (%) | 0.15% |
| Owned by Institutions (%) | 87.25% |
| Float | 893.13M |
Valuation Ratios
The trailing PE ratio is 51.57 and the forward PE ratio is 33.68. Eli Lilly's PEG ratio is 1.07.
| PE Ratio | 51.57 |
| Forward PE | 33.68 |
| PS Ratio | 15.94 |
| Forward PS | 12.82 |
| PB Ratio | 39.70 |
| P/TBV Ratio | 82.45 |
| P/FCF Ratio | 101.81 |
| P/OCF Ratio | 58.77 |
| PEG Ratio | 1.07 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 33.98, with an EV/FCF ratio of 105.30.
| EV / Earnings | 53.03 |
| EV / Sales | 16.43 |
| EV / EBITDA | 33.98 |
| EV / EBIT | 36.39 |
| EV / FCF | 105.30 |
Financial Position
The company has a current ratio of 1.55, with a Debt / Equity ratio of 1.79.
| Current Ratio | 1.55 |
| Quick Ratio | 0.72 |
| Debt / Equity | 1.79 |
| Debt / EBITDA | 1.47 |
| Debt / FCF | 4.59 |
| Interest Coverage | 29.91 |
Financial Efficiency
Return on equity (ROE) is 96.47% and return on invested capital (ROIC) is 29.95%.
| Return on Equity (ROE) | 96.47% |
| Return on Assets (ROA) | 17.60% |
| Return on Invested Capital (ROIC) | 29.95% |
| Return on Capital Employed (ROCE) | 35.87% |
| Revenue Per Employee | $1.26M |
| Profits Per Employee | $391,747 |
| Employee Count | 47,000 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 1.03 |
Taxes
In the past 12 months, Eli Lilly has paid $4.09 billion in taxes.
| Income Tax | 4.09B |
| Effective Tax Rate | 18.18% |
Stock Price Statistics
The stock price has increased by +33.60% in the last 52 weeks. The beta is 0.37, so Eli Lilly's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | +33.60% |
| 50-Day Moving Average | 943.18 |
| 200-Day Moving Average | 815.93 |
| Relative Strength Index (RSI) | 61.89 |
| Average Volume (20 Days) | 3,525,735 |
Short Selling Information
The latest short interest is 7.07 million, so 0.79% of the outstanding shares have been sold short.
| Short Interest | 7.07M |
| Short Previous Month | 6.44M |
| Short % of Shares Out | 0.79% |
| Short % of Float | 0.79% |
| Short Ratio (days to cover) | 1.56 |
Income Statement
In the last 12 months, Eli Lilly had revenue of $59.42 billion and earned $18.41 billion in profits. Earnings per share was $20.44.
| Revenue | 59.42B |
| Gross Profit | 49.34B |
| Operating Income | 26.83B |
| Pretax Income | 22.50B |
| Net Income | 18.41B |
| EBITDA | 28.73B |
| EBIT | 26.83B |
| Earnings Per Share (EPS) | $20.44 |
Balance Sheet
The company has $9.91 billion in cash and $42.58 billion in debt, giving a net cash position of -$32.34 billion or -$36.12 per share.
| Cash & Cash Equivalents | 9.91B |
| Total Debt | 42.58B |
| Net Cash | -32.34B |
| Net Cash Per Share | -$36.12 |
| Equity (Book Value) | 23.85B |
| Book Value Per Share | 26.56 |
| Working Capital | 21.93B |
Cash Flow
In the last 12 months, operating cash flow was $16.06 billion and capital expenditures -$6.79 billion, giving a free cash flow of $9.27 billion.
| Operating Cash Flow | 16.06B |
| Capital Expenditures | -6.79B |
| Free Cash Flow | 9.27B |
| FCF Per Share | $10.36 |
Margins
Gross margin is 83.03%, with operating and profit margins of 45.16% and 30.99%.
| Gross Margin | 83.03% |
| Operating Margin | 45.16% |
| Pretax Margin | 37.87% |
| Profit Margin | 30.99% |
| EBITDA Margin | 48.35% |
| EBIT Margin | 45.16% |
| FCF Margin | 15.60% |
Dividends & Yields
This stock pays an annual dividend of $6.92, which amounts to a dividend yield of 0.66%.
| Dividend Per Share | $6.92 |
| Dividend Yield | 0.66% |
| Dividend Growth (YoY) | 15.37% |
| Years of Dividend Growth | 11 |
| Payout Ratio | 30.48% |
| Buyback Yield | 0.41% |
| Shareholder Yield | 1.07% |
| Earnings Yield | 1.95% |
| FCF Yield | 0.98% |
Analyst Forecast
The average price target for Eli Lilly is $1,084.06, which is 2.82% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $1,084.06 |
| Price Target Difference | 2.82% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (5Y) | 16.99% |
| EPS Growth Forecast (5Y) | 29.83% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 16, 1997. It was a forward split with a ratio of 2:1.
| Last Split Date | Oct 16, 1997 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Eli Lilly has an Altman Z-Score of 6.49 and a Piotroski F-Score of 6.
| Altman Z-Score | 6.49 |
| Piotroski F-Score | 6 |